Calidi Biotherapeutics (CLDI)
XASE:CLDI
Top Page
Calidi Biotherapeutics
(NYSE MKT:CLDI)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.23
▼(-79.46% Downside)
Action:DowngradedDate:04/03/26
The score is weighed down primarily by weak financial performance (minimal revenue, large ongoing losses, and substantial cash burn) and very bearish technicals (price below key moving averages with negative MACD). Balance-sheet improvements and some positive operational/governance updates provide limited offset, while dilution-related corporate actions and a negative/unenlightening valuation signal keep the score near the low end of the range.
Positive Factors
Clinical-stage pipeline progress
Advancing CLD-401 toward first-in-human studies and targeting an IND by end-2026 materially reduces program risk over the medium term. GMP manufacturing and regulatory feedback de-risk operational execution, increasing the chance of achieving clinical milestones that enable partnering or non-dilutive funding.
Negative Factors
Substantial and persistent cash burn
Consistent large negative operating and free cash flow means the company cannot self-fund development and must access capital regularly. Over a 2-6 month horizon this structural burn heightens refinancing risk, can force hurried raises, and may delay or constrain clinical programs absent partner funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical-stage pipeline progress
Advancing CLD-401 toward first-in-human studies and targeting an IND by end-2026 materially reduces program risk over the medium term. GMP manufacturing and regulatory feedback de-risk operational execution, increasing the chance of achieving clinical milestones that enable partnering or non-dilutive funding.
Read all positive factors
Calidi Biotherapeutics (CLDI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.71M
Dividend YieldN/A
Average Volume (3M)164.15K
Price to Earnings (P/E)―
Beta (1Y)0.93
Revenue GrowthN/A
EPS Growth87.42%
CountryUS
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.57
Shares Outstanding10,895,725
10 Day Avg. Volume193,319
30 Day Avg. Volume164,153
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.34
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market Cap-0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.05
Enterprise Value/Ebitda0.09
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.52
Revenue Forecast (FY)N/A
Calidi Biotherapeutics Business Overview & Revenue Model
Company Description
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in m...
How the Company Makes Money
null...
Calidi Biotherapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
16
Very Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 45.00K | 449.00K |
| Gross Profit | -1.65M | 0.00 | -1.26M | -229.00K | 355.00K |
| EBITDA | -18.59M | -19.73M | -24.20M | -25.00M | -9.45M |
| Net Income | -19.91M | -22.14M | -29.22M | -25.43M | -10.93M |
Balance Sheet | |||||
| Total Assets | 8.86M | 14.18M | 10.02M | 2.60M | 3.39M |
| Cash, Cash Equivalents and Short-Term Investments | 5.60M | 9.59M | 2.05M | 372.00K | 2.14M |
| Total Debt | 2.56M | 7.04M | 7.24M | 5.99M | 5.18M |
| Total Liabilities | 5.10M | 12.21M | 18.25M | 53.04M | 26.00M |
| Stockholders Equity | 3.76M | 1.53M | -8.23M | -50.44M | -22.61M |
Cash Flow | |||||
| Free Cash Flow | -21.41M | -19.71M | -27.57M | -13.64M | -7.98M |
| Operating Cash Flow | -21.29M | -19.69M | -26.98M | -13.21M | -7.77M |
| Investing Cash Flow | -170.00K | -16.00K | -478.00K | -494.00K | -215.00K |
| Financing Cash Flow | 17.46M | 27.36M | 29.04M | 12.09M | 9.81M |
Calidi Biotherapeutics Technical Analysis
Negative
1.12
Price Trends
0.59
Negative
0.95
Negative
2.15
Negative
Market Momentum
-0.10
Negative
21.58
Positive
39.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLDI, the sentiment is Negative. The current price of 1.12 is above the 20-day moving average (MA) of 0.28, above the 50-day MA of 0.59, and below the 200-day MA of 2.15, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 21.58 is Positive, neither overbought nor oversold. The STOCH value of 39.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLDI.
Calidi Biotherapeutics Risk Analysis
Calidi Biotherapeutics disclosed 84 risk factors in its most recent earnings report. Calidi Biotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Calidi Biotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $4.96M | -0.04 | 9999.00% | ― | 12.45% | -544.23% | |
44 Neutral | $2.36M | -0.46 | -155.01% | ― | ― | 78.52% | |
43 Neutral | $4.11M | -0.31 | -46.34% | ― | ― | 70.71% | |
40 Underperform | $2.71M | -0.52 | ― | ― | ― | 87.42% |
* Healthcare Sector Average
CLDI
Calidi Biotherapeutics
0.26
-4.64
-94.76%
GLMD
Galmed Pharmaceuticals
0.79
-0.48
-37.70%
JAGX
Jaguar Animal Health
0.38
-4.74
-92.60%
ADIL
Adial Pharmaceuticals
1.56
-16.32
-91.27%
CDIO
Cardio Diagnostics Holdings
1.81
-8.55
-82.53%
Calidi Biotherapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Calidi Biotherapeutics Streamlines Board, Enhances Audit Oversight
Positive
Apr 2, 2026
On March 29, 2026, Calidi Biotherapeutics director Allan J. Camaisa notified the board’s Nominating and Corporate Governance Committee that he will allow his term to expire at the company’s 2026 annual stockholder meeting, with no disa...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Calidi Biotherapeutics Reports 2025 Results, Advances Oncology Pipeline
Negative
Mar 27, 2026
On March 27, 2026, Calidi Biotherapeutics reported fourth-quarter and full-year 2025 results, highlighting scientific and clinical progress alongside continued losses as it advances its oncology pipeline. The company formed a partnership with Avan...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Calidi Biotherapeutics Completes Dilutive Public Equity Offering
Negative
Mar 12, 2026
On March 6, 2026, Calidi Biotherapeutics, Inc. entered an underwriting agreement with Ladenburg Thalmann for an underwritten public offering of 2,278,731 common stock units and 9,815,900 pre-funded warrant units, raising about $6.03 million in gro...
Business Operations and StrategyRegulatory Filings and Compliance
Calidi Biotherapeutics Updates Corporate Presentation Under Regulation FD
Neutral
Feb 10, 2026
On February 6, 2026, Calidi Biotherapeutics, Inc. posted an updated corporate presentation on its website and furnished the same materials in connection with a Form 8-K filing. The company emphasized that the information was provided under Regulat...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Calidi Biotherapeutics Sets 2026 Priorities After 2025 Progress
Positive
Jan 29, 2026
On January 28, 2026, Calidi Biotherapeutics recapped its 2025 progress and outlined operational priorities for 2026, highlighting preclinical data presented in May and November 2025 that showed its RedTail platform and lead asset CLD-401 can avoid...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.